aspartic acid has been researched along with Alcoholism in 59 studies
Aspartic Acid: One of the non-essential amino acids commonly occurring in the L-form. It is found in animals and plants, especially in sugar cane and sugar beets. It may be a neurotransmitter.
aspartic acid : An alpha-amino acid that consists of succinic acid bearing a single alpha-amino substituent
L-aspartic acid : The L-enantiomer of aspartic acid.
Alcoholism: A primary, chronic disease with genetic, psychosocial, and environmental factors influencing its development and manifestations. The disease is often progressive and fatal. It is characterized by impaired control over drinking, preoccupation with the drug alcohol, use of alcohol despite adverse consequences, and distortions in thinking, most notably denial. Each of these symptoms may be continuous or periodic. (Morse & Flavin for the Joint Commission of the National Council on Alcoholism and Drug Dependence and the American Society of Addiction Medicine to Study the Definition and Criteria for the Diagnosis of Alcoholism: in JAMA 1992;268:1012-4)
| Excerpt | Relevance | Reference |
|---|---|---|
| "Ibudilast-treated participants had lower Cho in superior frontal white matter and nominally lower MI in pregenual anterior cingulate cortex." | 7.11 | Effects of ibudilast on central and peripheral markers of inflammation in alcohol use disorder: A randomized clinical trial. ( Alger, J; Burnette, E; Evans, CJ; Grodin, EN; Irwin, MR; London, ED; Meredith, LR; Miotto, K; Nieto, SJ; O'Neill, J; Ray, LA, 2022) |
| "To evaluate whether individuals with alcoholism who are heterozygous (Asp40/Asn40) or homozygous (Asp40/Asp40) for the OPRM1 Asp40 allele respond better to naltrexone." | 5.13 | An evaluation of mu-opioid receptor (OPRM1) as a predictor of naltrexone response in the treatment of alcohol dependence: results from the Combined Pharmacotherapies and Behavioral Interventions for Alcohol Dependence (COMBINE) study. ( Anton, RF; Couper, D; Goldman, D; O'Malley, S; Oroszi, G; Pettinati, H; Swift, R, 2008) |
| "Concentrations of N-acetylaspartate, choline-containing compounds, myo-inositol, and creatine plus phosphocreatine in frontal lobe gray matter and white matter were estimated in eight women and 17 men who were recently detoxified from long-term alcoholism." | 3.72 | Effects of alcoholism and gender on brain metabolism. ( Alhassoon, OM; Brown, GG; Gonzalez, R; Grant, I; Patterson, TL; Schweinsburg, BC; Taylor, MJ; Videen, JS, 2003) |
| "Ibudilast-treated participants had lower Cho in superior frontal white matter and nominally lower MI in pregenual anterior cingulate cortex." | 3.11 | Effects of ibudilast on central and peripheral markers of inflammation in alcohol use disorder: A randomized clinical trial. ( Alger, J; Burnette, E; Evans, CJ; Grodin, EN; Irwin, MR; London, ED; Meredith, LR; Miotto, K; Nieto, SJ; O'Neill, J; Ray, LA, 2022) |
| "Alcohol misuse and alcohol use disorder (AlUD) have neurobiological consequences." | 2.82 | Brain metabolite alterations related to alcohol use: a meta-analysis of proton magnetic resonance spectroscopy studies. ( Browning, BD; Green, R; Kirkland, AE; Leggio, L; Meyerhoff, DJ; Squeglia, LM, 2022) |
| "Alcohol use disorder is one of the leading causes of disability worldwide." | 2.80 | Naltrexone vs Placebo for the Treatment of Alcohol Dependence: A Randomized Clinical Trial. ( Berrettini, W; Gordon, AJ; Leong, SH; Lynch, KG; O'Brien, CP; Oslin, DW; Rukstalis, M, 2015) |
| "Posttraumatic stress disorder (PTSD) patients have low cortical concentrations of γ-aminobutyric acid (GABA) and elevated glutamate (Glu) as measured by proton magnetic resonance spectroscopy ((1)H MRS)." | 1.40 | A preliminary examination of cortical neurotransmitter levels associated with heavy drinking in posttraumatic stress disorder. ( Abé, C; Batki, SL; Meyerhoff, DJ; Pennington, DL, 2014) |
| "Chronic smoking in alcohol dependence is associated with abnormalities in brain morphology and metabolite levels in large lobar regions (e." | 1.39 | Chronic cigarette smoking in alcohol dependence: associations with cortical thickness and N-acetylaspartate levels in the extended brain reward system. ( Durazzo, TC; Gazdzinski, S; Meyerhoff, DJ; Mon, A, 2013) |
| "Chronic alcoholism is associated with altered brain metabolism, morphology and cognitive abilities." | 1.37 | Brain metabolite changes in alcoholism: localized proton magnetic resonance spectroscopy study of the occipital lobe. ( Bhattacharya, M; Deshpande, SN; Khushu, S; Kumar, P; Modi, S; Tripathi, RP, 2011) |
| "Alcoholism is highly prevalent among bipolar disorder (BD) patients, and its presence is associated with a worse outcome and refractoriness to treatment of the mood disorder." | 1.36 | Bipolar disorder comorbid with alcoholism: a 1H magnetic resonance spectroscopy study. ( Chen, HH; Hatch, JP; Lafer, B; Monkul, ES; Nery, FG; Nicoletti, MA; Soares, JC; Stanley, JA, 2010) |
| "Recent studies demonstrated that alcohol dependence and excessive alcohol consumption are associated with increased rates of obesity." | 1.36 | Body mass index is associated with brain metabolite levels in alcohol dependence--a multimodal magnetic resonance study. ( Durazzo, TC; Gazdzinski, S; Meyerhoff, DJ; Mon, A, 2010) |
| "Co-morbidities of PTSD, notably alcohol abuse, may have contributed to the inconsistency." | 1.35 | Abnormal N-acetylaspartate in hippocampus and anterior cingulate in posttraumatic stress disorder. ( Fox-Bosetti, S; Kornak, J; Lenoci, M; Marmar, CR; Neylan, TC; Samuelson, KW; Schuff, N; Studholme, C; Weiner, MW, 2008) |
| "Chronic alcohol abuse results in morphological, metabolic, and functional brain damage which may, to some extent, be reversible with early effects upon abstinence." | 1.34 | Manifestations of early brain recovery associated with abstinence from alcoholism. ( Bartsch, AJ; Bendszus, M; Biller, A; De Stefano, N; Homola, G; Jenkinson, M; Smith, SM; Solymosi, L; Weijers, HG; Wiesbeck, GA, 2007) |
| "Oral arginine aspartate treatment effects (acute administration: 1 g 30 minutes after load, chronic administration: 0." | 1.26 | [Arginine aspartate effects on rabbit acute and chronic alcoholization (author's transl)]. ( Elsair, J; Hattab, F; Poey, J; Reggabi, M; Spinner, C; Zidane, C, 1978) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 11 (18.64) | 18.7374 |
| 1990's | 6 (10.17) | 18.2507 |
| 2000's | 22 (37.29) | 29.6817 |
| 2010's | 17 (28.81) | 24.3611 |
| 2020's | 3 (5.08) | 2.80 |
| Authors | Studies |
|---|---|
| Kirkland, AE | 1 |
| Browning, BD | 1 |
| Green, R | 1 |
| Leggio, L | 1 |
| Meyerhoff, DJ | 10 |
| Squeglia, LM | 1 |
| Grodin, EN | 1 |
| Nieto, SJ | 1 |
| Meredith, LR | 1 |
| Burnette, E | 1 |
| O'Neill, J | 1 |
| Alger, J | 1 |
| London, ED | 1 |
| Miotto, K | 1 |
| Evans, CJ | 1 |
| Irwin, MR | 1 |
| Ray, LA | 2 |
| Morley, KC | 1 |
| Lagopoulos, J | 1 |
| Logge, W | 1 |
| Chitty, K | 1 |
| Moustafa, AA | 1 |
| Haber, PS | 1 |
| Prisciandaro, JJ | 2 |
| Schacht, JP | 2 |
| Prescot, AP | 2 |
| Renshaw, PF | 3 |
| Brown, TR | 2 |
| Anton, RF | 3 |
| Griffin, WC | 1 |
| Haun, HL | 1 |
| Hazelbaker, CL | 1 |
| Ramachandra, VS | 1 |
| Becker, HC | 1 |
| Pennington, DL | 1 |
| Abé, C | 1 |
| Batki, SL | 1 |
| Oslin, DW | 1 |
| Leong, SH | 1 |
| Lynch, KG | 1 |
| Berrettini, W | 1 |
| O'Brien, CP | 1 |
| Gordon, AJ | 1 |
| Rukstalis, M | 1 |
| Zahr, NM | 2 |
| Carr, RA | 1 |
| Rohlfing, T | 2 |
| Mayer, D | 2 |
| Sullivan, EV | 3 |
| Colrain, IM | 1 |
| Pfefferbaum, A | 3 |
| Frischknecht, U | 1 |
| Hermann, D | 2 |
| Tunc-Skarka, N | 1 |
| Wang, GY | 1 |
| Sack, M | 1 |
| van Eijk, J | 1 |
| Demirakca, T | 1 |
| Falfan-Melgoza, C | 1 |
| Krumm, B | 1 |
| Dieter, S | 1 |
| Spanagel, R | 1 |
| Kiefer, F | 1 |
| Mann, KF | 1 |
| Sommer, WH | 1 |
| Ende, G | 2 |
| Weber-Fahr, W | 2 |
| Wang, JJ | 1 |
| Durazzo, TC | 7 |
| Gazdzinski, S | 7 |
| Yeh, PH | 2 |
| Mon, A | 4 |
| Machado, A | 1 |
| Soares-Fernandes, J | 1 |
| Ribeiro, M | 1 |
| Rodrigues, M | 1 |
| Cerqueira, J | 1 |
| Ferreira, C | 1 |
| Nery, FG | 1 |
| Stanley, JA | 1 |
| Chen, HH | 1 |
| Hatch, JP | 1 |
| Nicoletti, MA | 1 |
| Monkul, ES | 1 |
| Lafer, B | 1 |
| Soares, JC | 1 |
| Modi, S | 1 |
| Bhattacharya, M | 1 |
| Kumar, P | 1 |
| Deshpande, SN | 1 |
| Tripathi, RP | 1 |
| Khushu, S | 1 |
| Hasak, MP | 1 |
| Hsu, O | 1 |
| Vinco, S | 1 |
| Orduna, J | 1 |
| Luong, R | 1 |
| Licata, SC | 1 |
| Pathak, V | 1 |
| Hutchison, KE | 1 |
| Ashenhurst, JR | 1 |
| Morrow, AL | 1 |
| Weerts, EM | 1 |
| McCaul, ME | 1 |
| Kuwabara, H | 1 |
| Yang, X | 1 |
| Xu, X | 1 |
| Dannals, RF | 1 |
| Frost, JJ | 1 |
| Wong, DF | 1 |
| Wand, GS | 1 |
| Xia, Y | 1 |
| Ma, D | 1 |
| Hu, J | 1 |
| Tang, C | 1 |
| Wu, Z | 1 |
| Liu, L | 1 |
| Xin, F | 1 |
| Schweinsburg, BC | 3 |
| Alhassoon, OM | 3 |
| Taylor, MJ | 3 |
| Gonzalez, R | 1 |
| Videen, JS | 3 |
| Brown, GG | 2 |
| Patterson, TL | 3 |
| Grant, I | 3 |
| Lee, H | 1 |
| Holburn, GH | 1 |
| Price, RR | 1 |
| LABORIE, G | 1 |
| Neylan, TC | 2 |
| Lenoci, M | 2 |
| Rothlind, J | 1 |
| Metzler, TJ | 1 |
| Schuff, N | 3 |
| Du, AT | 1 |
| Franklin, KW | 1 |
| Weiss, DS | 1 |
| Weiner, MW | 4 |
| Marmar, CR | 2 |
| Adalsteinsson, E | 1 |
| Welzel, H | 1 |
| Walter, S | 1 |
| Diehl, A | 1 |
| Heinz, A | 1 |
| Mann, K | 2 |
| Mason, GF | 2 |
| Petrakis, IL | 1 |
| de Graaf, RA | 1 |
| Gueorguieva, R | 1 |
| Guidone, E | 1 |
| Coric, V | 1 |
| Epperson, CN | 1 |
| Rothman, DL | 1 |
| Krystal, JH | 1 |
| Arias, A | 1 |
| Feinn, R | 1 |
| Kranzler, HR | 1 |
| Rothlind, JC | 1 |
| Banys, P | 2 |
| Mueller, S | 1 |
| Chao, L | 1 |
| Sacrey, DT | 1 |
| Laxer, K | 1 |
| Bartsch, AJ | 1 |
| Homola, G | 1 |
| Biller, A | 1 |
| Smith, SM | 1 |
| Weijers, HG | 1 |
| Wiesbeck, GA | 1 |
| Jenkinson, M | 1 |
| De Stefano, N | 1 |
| Solymosi, L | 1 |
| Bendszus, M | 1 |
| Hardin, D | 1 |
| Fox-Bosetti, S | 1 |
| Samuelson, KW | 1 |
| Studholme, C | 1 |
| Kornak, J | 1 |
| Oroszi, G | 1 |
| O'Malley, S | 1 |
| Couper, D | 1 |
| Swift, R | 1 |
| Pettinati, H | 1 |
| Goldman, D | 1 |
| Daunderer, M | 2 |
| Martin, PR | 1 |
| Gibbs, SJ | 1 |
| Nimmerrichter, AA | 1 |
| Riddle, WR | 1 |
| Welch, LW | 1 |
| Willcott, MR | 1 |
| Aliyev, NA | 1 |
| Aliyev, ZN | 1 |
| Aliguliyev, AR | 1 |
| Tsai, GE | 1 |
| Ragan, P | 1 |
| Chang, R | 1 |
| Chen, S | 1 |
| Linnoila, VM | 1 |
| Coyle, JT | 1 |
| Dahchour, A | 1 |
| De Witte, P | 1 |
| Bolo, N | 1 |
| Nédélec, JF | 1 |
| Muzet, M | 1 |
| Durbin, P | 1 |
| Macher, JP | 1 |
| Seitz, D | 1 |
| Widmann, U | 1 |
| Seeger, U | 1 |
| Nägele, T | 1 |
| Klose, U | 1 |
| Grodd, W | 1 |
| Braunová, Z | 1 |
| Kasparová, S | 1 |
| Mlynárik, V | 1 |
| Mierisová, S | 1 |
| Liptaj, T | 1 |
| Tkác, I | 1 |
| Gvozdjáková, A | 1 |
| Berger, F | 1 |
| Grütters, G | 1 |
| Ritz-Timme, S | 1 |
| Reichelt, JA | 1 |
| Nölle, B | 1 |
| Favalli, L | 1 |
| Rozza, A | 1 |
| Frattini, P | 1 |
| Masoero, E | 1 |
| Scelsi, R | 1 |
| Pascale, A | 1 |
| Govoni, S | 1 |
| Cederbaum, AI | 2 |
| Rubin, E | 2 |
| Dicker, E | 1 |
| Lieber, CS | 1 |
| Poey, J | 1 |
| Elsair, J | 1 |
| Zidane, C | 1 |
| Reggabi, M | 1 |
| Hattab, F | 1 |
| Spinner, C | 1 |
| Rassouli, ME | 1 |
| Ikeda, H | 1 |
| Otsuki, S | 1 |
| Olbrich, R | 1 |
| Watzl, H | 1 |
| Völter, M | 1 |
| Siedow, H | 1 |
| Ripamonti, C | 1 |
| Hunold, W | 1 |
| Boucharlat, J | 1 |
| Salomon, C | 1 |
| Maitre, A | 1 |
| Pelat, J | 1 |
| Wolf, R | 1 |
| Madeddu, A | 1 |
| Sacchi, C | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Pharmacogenetic Response to Naltrexone for Alcohol Dependence[NCT00831272] | Phase 4 | 221 participants (Actual) | Interventional | 2009-01-05 | Completed | ||
| Imaging Framework for Testing GABAergic/Glutamatergic Drugs in Bipolar Alcoholics[NCT03220776] | Phase 2 | 54 participants (Actual) | Interventional | 2017-08-07 | Completed | ||
| Multimodal Imaging of Progesterone/Neurosteroid Effects in Nicotine Addiction[NCT01954966] | Phase 4 | 81 participants (Actual) | Interventional | 2010-11-30 | Completed | ||
| COMBINE: Effect of Combined Pharmacotherapies and Behavioral Interventions[NCT00006206] | Phase 3 | 1,375 participants | Interventional | 1997-08-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
(NCT00831272)
Timeframe: 12 weeks
| Intervention | percentage of heavy drinking days (Mean) |
|---|---|
| Naltrexone Group ASP 40 Group | 18.9 |
| Placebo Group ASP 40 Group | 17.9 |
| Naltrexone Group ASN 40 Group | 14.5 |
| Placebo Group ASN 40 Group | 21.7 |
Concentrations of GABA+, referenced to unsuppressed water and corrected for within-voxel CSF proportion, in dorsal anterior cingulate cortex measured via Proton Magnetic Resonance Spectroscopy (i.e., MEGA-PRESS). (NCT03220776)
Timeframe: Day 5 of each experimental condition
| Intervention | mmol/kg (Mean) |
|---|---|
| N-Acetylcysteine | 3.90 |
| Gabapentin | 3.93 |
| Placebo Oral Tablet | 3.73 |
Concentrations of Glx (i.e., glutamate + glutamine), referenced to unsuppressed water and corrected for within-voxel CSF proportion, in dorsal anterior cingulate cortex measured via Proton Magnetic Resonance Spectroscopy. (NCT03220776)
Timeframe: Day 5 of each experimental condition
| Intervention | mmol/kg (Mean) |
|---|---|
| N-Acetylcysteine | 21.59 |
| Gabapentin | 21.69 |
| Placebo Oral Tablet | 22.25 |
Craving will be assessed using the Brief Questionnaire on Smoking Urges (BQSU). It ranges from 7-70 with higher levels indicating higher levels of nicotine craving. (NCT01954966)
Timeframe: Day 1 (pre and post smoking session, day 2 (pre and post scan), day 3 (AM and PM), day 4 (AM and PM), day 5 (pre and post smoking session)
| Intervention | score on a scale (Mean) | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Day 1; pre-1st smoking session | Day 1; post-1st smoking session | Day 2; pre-1st scan | Day 2; post-2nd scan | Day 3; abstinence AM | Day 3; abstinence PM | Day 4; abstinence AM | Day 4; abstinence PM | Day 5; after scan, pre-smoking | Day 5; after smoking | |
| Progesterone 200 mg Capsules | 40.89 | 30.45 | 38.47 | 38.81 | 41.91 | 40.84 | 40.90 | 39.23 | 41.95 | 27.64 |
| Progesterone 200 mg Look-alike Capsules | 41.94 | 25.77 | 34.34 | 37.98 | 41.82 | 42.03 | 40.29 | 37.68 | 42.38 | 28.22 |
"GABA concentrations (collected in the Dorsal Anterior Cingulate Cortex [DACC]) will be obtained using the non-invasive neuroimaging method of proton magnetic resonance spectroscopy (1H-MRS) both before and after placebo administration and smoking abstinence. In total subjects will undergo 6 1H-MRS scans. The 6 1H-MRS scans take place over a period of approximately 1-2 months. Each paradigm (placebo/progesterone) takes approximately one week, with an approximately two-week wash in between paradigms for men and an approximately 1-month wash in between paradigms for women. The subject will undergo a smoking session on Test Day #1 and Test Day #5, MRS scans are conducted on Test Day #2 (2 scans) and Test Day #5 (1 scan).~Minimal data is available for the primary outcome due to substantial issues with the 7T scanner. All subsequent scans were conducted on a 3T scanner which does not have the capacity to collect data on GABA." (NCT01954966)
Timeframe: Test Day #2 and Test Day #5 - 6 total scans over the period of 2-3 months.
| Intervention | mg/dl (Mean) | ||
|---|---|---|---|
| Test day 2 (baseline, pre-scan) | Test day 2 (post-scan) | Test day 5 (pre-smoking) | |
| Progesterone 200 mg Capsules | 1.23 | 1.28 | 1.21 |
| Progesterone 200 mg Look-alike Capsules | 1.17 | 1.24 | 1.17 |
"GABA concentrations (collected in the Dorsolateral Pre-Frontal Cortex [DLPFC]) will be obtained using the non-invasive neuroimaging method of proton magnetic resonance spectroscopy (1H-MRS) both before and after placebo administration and smoking abstinence. In total subjects will undergo 6 1H-MRS scans. The 6 1H-MRS scans take place over a period of approximately 1-2 months. Each paradigm (placebo/progesterone) takes approximately one week, with an approximately two-week wash in between paradigms for men and an approximately 1-month wash in between paradigms for women. The subject will undergo a smoking session on Test Day #1 and Test Day #5, MRS scans are conducted on Test Day #2 (2 scans) and Test Day #5 (1 scan).~Minimal data is available for the primary outcome due to substantial issues with the 7T scanner. All subsequent scans were conducted on a 3T scanner which does not have the capacity to collect data on GABA." (NCT01954966)
Timeframe: Test Day #2 and Test Day #5 - 6 total scans over the period of 2-3 months.
| Intervention | mg/dl (Mean) | ||
|---|---|---|---|
| Day 2- pre scan | Day 2- post scan | Day 5- after scan, pre smoking | |
| Progesterone 200 mg Capsules | 1.18 | 1.05 | 1.06 |
| Progesterone 200 mg Look-alike Capsules | 1.20 | 0.98 | 1.11 |
Nicotine Effects Questionnaire (NEQ) question: feels bad effects of nicotine. Score ranges from 0 to 100 with higher levels indicating feeling more bad effects of nicotine after smoking. (NCT01954966)
Timeframe: Day 1 (pre smoking session), Day 5 (post smoking session)
| Intervention | score on a scale (Mean) | |
|---|---|---|
| Day 1; pre-1st smoking session | Day 5; after smoking | |
| Progesterone 200 mg Capsules | 26.25 | 25.39 |
| Progesterone 200 mg Look-alike Capsules | 25.92 | 28.70 |
NEQ question: feels good effects of nicotine. Score ranges from 0 to 100 with higher levels indicating feeling more good effects of nicotine after smoking. (NCT01954966)
Timeframe: Day 1 (pre smoking session), Day 5 (post smoking session)
| Intervention | score on a scale (Mean) | |
|---|---|---|
| Day 1; pre-1st smoking session | Day 5; after smoking | |
| Progesterone 200 mg Capsules | 67.72 | 67.84 |
| Progesterone 200 mg Look-alike Capsules | 67.84 | 64.72 |
Nicotine Effects Questionnaire (NEQ) question: feels strength of nicotine. Score ranges from 0 to 100 with higher levels indicating feeling stronger effects of nicotine after smoking. (NCT01954966)
Timeframe: Day 1 (pre smoking session), Day 5 (post smoking session)
| Intervention | score on a scale (Mean) | |
|---|---|---|
| Day 1; pre-1st smoking session | Day 5; after smoking | |
| Progesterone 200 mg Capsules | 71.45 | 74.87 |
| Progesterone 200 mg Look-alike Capsules | 71.01 | 75.25 |
Nicotine Effects Questionnaire (NEQ) question: feels head rush. Score ranges from 0 to 100 with higher levels indicating feeling stronger/more intense head rush after smoking. (NCT01954966)
Timeframe: Day 1 (pre smoking session), Day 5 (post smoking session)
| Intervention | score on a scale (Mean) | |
|---|---|---|
| Day 1; pre-1st smoking session | Day 5; after smoking | |
| Progesterone 200 mg Capsules | 30.58 | 40.23 |
| Progesterone 200 mg Look-alike Capsules | 29.38 | 42.48 |
Positive and Negative Affect Schedule (PANAS) Negative Affect Score. Ranges from 10-50 with higher scores representing higher levels of negative affect. (NCT01954966)
Timeframe: Day 1 (pre and post smoking session, day 2 (pre and post scan), day 3 (AM and PM), day 4 (AM and PM), day 5 (pre and post smoking session)
| Intervention | score on a scale (Mean) | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Day 1; pre-1st smoking session | Day 1; post-1st smoking session | Day 2; pre-1st scan | Day 2; post-2nd scan | Day 3; abstinence AM | Day 3; abstinence PM | Day 4; abstinence AM | Day 4; abstinence PM | Day 5; after scan, pre-smoking | Day 5; after smoking | |
| Progesterone 200 mg Capsules | 11.94 | 10.64 | 11.25 | 11.59 | 12.31 | 13.07 | 12.51 | 12.90 | 12.55 | 11.41 |
| Progesterone 200 mg Look-alike Capsules | 11.43 | 10.57 | 11.03 | 11.49 | 13.01 | 12.89 | 13.06 | 13.16 | 12.18 | 11.94 |
Positive and Negative Affect Schedule (PANAS) Positive Affect Score. Ranges from 10-50 with higher scores representing higher levels of positive affect. (NCT01954966)
Timeframe: Day 1 (pre and post smoking session, day 2 (pre and post scan), day 3 (AM and PM), day 4 (AM and PM), day 5 (pre and post smoking session)
| Intervention | score on a scale (Mean) | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Day 1; pre-1st smoking session | Day 1; post-1st smoking session | Day 2; pre-1st scan | Day 2; post-2nd scan | Day 3; abstinence AM | Day 3; abstinence PM | Day 4; abstinence AM | Day 4; abstinence PM | Day 5; after scan, pre-smoking | Day 5; after smoking | |
| Progesterone 200 mg Capsules | 37.10 | 35.72 | 36.08 | 33.51 | 32.57 | 32.34 | 32.56 | 33.25 | 33.45 | 33.10 |
| Progesterone 200 mg Look-alike Capsules | 37.23 | 36.11 | 36.55 | 34.17 | 33.30 | 32.81 | 32.03 | 32.61 | 32.53 | 33.76 |
Profile of Mood State (POMS) Subscale: Vigor. Subscale ranges from 0 to 32, with higher levels indicating higher levels of vigor. (NCT01954966)
Timeframe: Day 2 (pre and post scan), Day 5 (pre smoking session)
| Intervention | score on a scale (Mean) | ||
|---|---|---|---|
| Day 2; pre-1st scan | Day 2; post-2nd scan | Day 5; after scan, pre-smoking | |
| Progesterone 200 mg Capsules | 18.71 | 16.74 | 16.71 |
| Progesterone 200 mg Look-alike Capsules | 18.71 | 16.73 | 16.39 |
Profile of Mood States (POMS) Subscale: Anger-Hostility. This scale ranges from 0 to 48 with higher levels indicating higher levels of anger/hostility. (NCT01954966)
Timeframe: Day 2 (pre and post scan), Day 5 (pre smoking session)
| Intervention | score on a scale (Mean) | ||
|---|---|---|---|
| Day 2; pre-1st scan | Day 2; post-2nd scan | Day 5; after scan, pre-smoking | |
| Progesterone 200 mg Capsules | 0.94 | 1.55 | 2.70 |
| Progesterone 200 mg Look-alike Capsules | 0.83 | 1.41 | 2.36 |
Profile of Mood States (POMS) Subscale: Confusion-Bewilderment. Ranges from 0 to 28 with higher levels indicating higher levels of confusion/bewilderment. (NCT01954966)
Timeframe: Day 2 (pre and post scan), Day 5 (pre smoking session)
| Intervention | score on a scale (Mean) | ||
|---|---|---|---|
| Day 2; pre-1st scan | Day 2; post-2nd scan | Day 5; after scan, pre-smoking | |
| Progesterone 200 mg Capsules | 2.47 | 2.95 | 3.46 |
| Progesterone 200 mg Look-alike Capsules | 2.31 | 2.98 | 2.80 |
Profile of Mood States (POMS) Subscale: Depression-Dejection. This subscale ranges from 0-60 with higher levels indicating greater depression/dejection. (NCT01954966)
Timeframe: Day 2 (pre and post scan), Day 5 (pre smoking session)
| Intervention | score on a scale (Mean) | ||
|---|---|---|---|
| Day 2; pre-1st scan | Day 2; post-2nd scan | Day 5; after scan, pre-smoking | |
| Progesterone 200 mg Capsules | 1.09 | 1.30 | 1.66 |
| Progesterone 200 mg Look-alike Capsules | 0.64 | 0.88 | 1.81 |
Profile of Mood States (POMS) Subscale: Fatigue. This subscale ranges from 0 to 28 with higher scores indicating higher levels of fatigue. (NCT01954966)
Timeframe: Day 2 (pre and post scan), Day 5 (pre smoking session)
| Intervention | score on a scale (Mean) | ||
|---|---|---|---|
| Day 2; pre-1st scan | Day 2; post-2nd scan | Day 5; after scan, pre-smoking | |
| Progesterone 200 mg Capsules | 2.17 | 2.84 | 3.66 |
| Progesterone 200 mg Look-alike Capsules | 1.77 | 3.63 | 3.10 |
Profile of Mood States (POMS) Subscale: Tension-Anxiety. This subscale ranges from 0-28 with higher levels indicating greater tension/anxiety. (NCT01954966)
Timeframe: Day 2 (pre and post scan), Day 5 (pre smoking session)
| Intervention | score on a scale (Mean) | ||
|---|---|---|---|
| Day 2; pre-1st scan | Day 2; post- 2nd scan | Day 5; after scan, pre-smoking | |
| Progesterone 200 mg Capsules | 2.88 | 3.55 | 4.85 |
| Progesterone 200 mg Look-alike Capsules | 2.57 | 3.11 | 3.70 |
Withdrawal symptoms will be measured using the Nicotine Withdrawal Symptoms Checklist (NWSC). The scale ranges from a minimum of 0 to a maximum of 28, with higher scores indicating greater withdrawal (more withdrawal symptoms, higher intensity/severity of withdrawal). (NCT01954966)
Timeframe: Day 1 (pre and post smoking session, day 2 (pre and post scan), day 3 (AM and PM), day 4 (AM and PM), day 5 (pre and post smoking session)
| Intervention | score on a scale (Mean) | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Nicotine withdrawal symptoms checklist (NWSC); day 1 pre 1st smoking session | Nicotine withdrawal symptoms checklist (NWSC); day 1 post 1st smoking session | Nicotine withdrawal symptoms checklist (NWSC); day 2 pre-scan | Nicotine withdrawal symptoms checklist (NWSC); day 2 post-scan | Nicotine withdrawal symptoms checklist (NWSC); day 3 abstinence AM | Nicotine withdrawal symptoms checklist (NWSC); day 3 abstinence PM | Nicotine withdrawal symptoms checklist (NWSC); day 4 abstinence AM | Nicotine withdrawal symptoms checklist (NWSC); day 4 abstinence PM | Nicotine withdrawal symptoms checklist (NWSC); day 5 pre-smoking | Nicotine withdrawal symptoms checklist (NWSC); day 5 post-smoking | |
| Progesterone 200 mg Capsules | 6.00 | 4.84 | 5.67 | 5.37 | 7.07 | 6.99 | 7.33 | 7.19 | 7.01 | 4.60 |
| Progesterone 200 mg Look-alike Capsules | 6.15 | 4.48 | 4.92 | 5.25 | 7.62 | 7.88 | 7.66 | 7.32 | 7.34 | 4.82 |
Craving will also be assessed using the Tiffany Questionnaire for Smoking Urges. It ranges from 32 to 224 with higher scores indicated higher levels of smoking urges/craving. (NCT01954966)
Timeframe: Day 1 (pre smoking session, day 3 (PM), day 4 (PM), day 5 (pre smoking session)
| Intervention | score on a scale (Mean) | |||
|---|---|---|---|---|
| Day 1; pre-1st smoking session | Day 3; abstinence PM | Day 4; abstinence PM | Day 5; after scan, pre-smoking | |
| Progesterone 200 mg Capsules | 143.45 | 138.46 | 139.11 | 146.22 |
| Progesterone 200 mg Look-alike Capsules | 140.31 | 140.77 | 135.88 | 141.08 |
Visual Analog Scale (VAS) question: Anxious. Scale ranges from 0 to 100 with higher levels indicating greater intensity of symptom/feeling. (NCT01954966)
Timeframe: Day 2 (pre and post scan), day 3 (AM and PM), day 4 (AM and PM), day 5 (pre and post smoking session)
| Intervention | score on a scale (Mean) | |||||||
|---|---|---|---|---|---|---|---|---|
| Day 2; pre-1st scan | Day 2; post-2nd scan | Day 3; abstinence AM | Day 3; abstinence PM | Day 4; abstinence AM | Day 4; abstinence PM | Day 5; after scan, pre-smoking | Day 5; after smoking | |
| Progesterone 200 mg Capsules | 16.69 | 15.02 | 20.20 | 16.38 | 18.46 | 15.88 | 17.81 | 16.26 |
| Progesterone 200 mg Look-alike Capsules | 15.62 | 12.65 | 17.38 | 20.23 | 15.08 | 15.63 | 19.05 | 15.30 |
Visual Analog Scale (VAS) question: Calm. Scale ranges from 0 to 100 with higher levels indicating greater intensity of symptom/feeling. (NCT01954966)
Timeframe: Day 2 (pre and post scan), day 3 (AM and PM), day 4 (AM and PM), day 5 (pre and post smoking session)
| Intervention | score on a scale (Mean) | |||||||
|---|---|---|---|---|---|---|---|---|
| Day 2; pre-1st scan | Day 2; post-2nd scan | Day 3; abstinence AM | Day 3; abstinence PM | Day 4; abstinence AM | Day 4; abstinence PM | Day 5; after scan, pre-smoking | Day 5; after smoking | |
| Progesterone 200 mg Capsules | 74.35 | 73.15 | 65.65 | 58.92 | 60.23 | 65.47 | 67.60 | 69.27 |
| Progesterone 200 mg Look-alike Capsules | 76.52 | 69.23 | 61.15 | 52.44 | 57.97 | 62.48 | 61.02 | 70.52 |
Visual Analog Scale (VAS) question: Depressed. Scale ranges from 0 to 100 with higher levels indicating greater intensity of symptom/feeling. (NCT01954966)
Timeframe: Day 2 (pre and post scan), day 3 (AM and PM), day 4 (AM and PM), day 5 (pre and post smoking session)
| Intervention | score on a scale (Mean) | |||||||
|---|---|---|---|---|---|---|---|---|
| Day 2; pre-1st scan | Day 2; post-2nd scan | Day 3; abstinence AM | Day 3; abstinence PM | Day 4; abstinence AM | Day 4; abstinence PM | Day 5; after scan, pre-smoking | Day 5; after smoking | |
| Progesterone 200 mg Capsules | 3.97 | 4.99 | 6.43 | 4.61 | 5.51 | 5.67 | 2.64 | 2.53 |
| Progesterone 200 mg Look-alike Capsules | 2.87 | 5.55 | 6.85 | 4.58 | 5.17 | 5.73 | 5.26 | 4.89 |
Visual Analog Scale (VAS) question: Drowsy. Scale ranges from 0 to 100 with higher levels indicating greater intensity of symptom/feeling. (NCT01954966)
Timeframe: Day 2 (pre and post scan), day 3 (AM and PM), day 4 (AM and PM), day 5 (pre and post smoking session)
| Intervention | score on a scale (Mean) | |||||||
|---|---|---|---|---|---|---|---|---|
| Day 2; pre-1st scan | Day 2; post-2nd scan | Day 3; abstinence AM | Day 3; abstinence PM | Day 4; abstinence AM | Day 4; abstinence PM | Day 5; after scan, pre-smoking | Day 5; after smoking | |
| Progesterone 200 mg Capsules | 16.63 | 24.25 | 17.14 | 24.71 | 19.56 | 19.84 | 23.01 | 20.45 |
| Progesterone 200 mg Look-alike Capsules | 14.29 | 30.17 | 15.43 | 24.36 | 18.32 | 20.50 | 21.01 | 21.45 |
Visual Analog Scale (VAS) question: Energetic. Scale ranges from 0 to 100 with higher levels indicating greater intensity of symptom/feeling. (NCT01954966)
Timeframe: Day 2 (pre and post scan), day 3 (AM and PM), day 4 (AM and PM), day 5 (pre and post smoking session)
| Intervention | score on a scale (Mean) | |||||||
|---|---|---|---|---|---|---|---|---|
| Day 2; pre-1st scan | Day 2; post-2nd scan | Day 3; abstinence AM | Day 3; abstinence PM | Day 4; abstinence AM | Day 4; abstinence PM | Day 5; after scan, pre-smoking | Day 5; after smoking | |
| Progesterone 200 mg Capsules | 54.86 | 55.18 | 56.14 | 56.13 | 55.62 | 53.45 | 51.47 | 54.79 |
| Progesterone 200 mg Look-alike Capsules | 67.01 | 21.03 | 58.11 | 50.12 | 54.89 | 56.77 | 56.64 | 54.70 |
Visual Analog Scale (VAS) question: Happy. Scale ranges from 0 to 100 with higher levels indicating greater intensity of symptom/feeling. (NCT01954966)
Timeframe: Day 2 (pre and post scan), day 3 (AM and PM), day 4 (AM and PM), day 5 (pre and post smoking session)
| Intervention | score on a scale (Mean) | |||||||
|---|---|---|---|---|---|---|---|---|
| Day 2; pre-1st scan | Day 2; post-2nd scan | Day 3; abstinence AM | Day 3; abstinence PM | Day 4; abstinence AM | Day 4; abstinence PM | Day 5; after scan, pre-smoking | Day 5; after smoking | |
| Progesterone 200 mg Capsules | 76.62 | 70.98 | 66.22 | 65.10 | 62.76 | 61.99 | 66.59 | 70.07 |
| Progesterone 200 mg Look-alike Capsules | 79.70 | 71.34 | 64.04 | 61.30 | 60.58 | 63.95 | 63.46 | 67.87 |
Visual Analog Scale (VAS) question: Headache. Scale ranges from 0 to 100 with higher levels indicating greater intensity of symptom/feeling. (NCT01954966)
Timeframe: Day 2 (pre and post scan), day 3 (AM and PM), day 4 (AM and PM), day 5 (pre and post smoking session)
| Intervention | score on a scale (Mean) | |||||||
|---|---|---|---|---|---|---|---|---|
| Day 2; pre-1st scan | Day 2; post-2nd scan | Day 3; abstinence AM | Day 3; abstinence PM | Day 4; abstinence AM | Day 4; abstinence PM | Day 5; after scan, pre-smoking | Day 5; after smoking | |
| Progesterone 200 mg Capsules | 6.50 | 5.74 | 9.15 | 8.86 | 10.88 | 11.83 | 9.05 | 11.93 |
| Progesterone 200 mg Look-alike Capsules | 7.59 | 9.39 | 14.71 | 10.93 | 7.70 | 12.78 | 13.36 | 11.67 |
Visual Analog Scale (VAS) question: Heartburn. Scale ranges from 0 to 100 with higher levels indicating greater intensity of symptom/feeling. (NCT01954966)
Timeframe: Day 2 (pre and post scan), day 3 (AM and PM), day 4 (AM and PM), day 5 (pre and post smoking session)
| Intervention | score on a scale (Mean) | |||||||
|---|---|---|---|---|---|---|---|---|
| Day 2; pre-1st scan | Day 2; post-2nd scan | Day 3; abstinence AM | Day 3; abstinence PM | Day 4; abstinence AM | Day 4; abstinence PM | Day 5; after scan, pre-smoking | Day 5; after smoking | |
| Progesterone 200 mg Capsules | 3.11 | 4.30 | 5.46 | 6.00 | 7.31 | 5.51 | 4.33 | 4.56 |
| Progesterone 200 mg Look-alike Capsules | 2.35 | 4.06 | 3.27 | 4.55 | 6.50 | 5.56 | 5.30 | 6.37 |
Visual Analog Scale (VAS) question: Hunger. Scale ranges from 0 to 100 with higher levels indicating greater intensity of symptom/feeling. (NCT01954966)
Timeframe: Day 2 (pre and post scan), day 3 (AM and PM), day 4 (AM and PM), day 5 (pre and post smoking session)
| Intervention | score on a scale (Mean) | |||||||
|---|---|---|---|---|---|---|---|---|
| Day 2; pre-1st scan | Day 2; post-2nd scan | Day 3; abstinence AM | Day 3; abstinence PM | Day 4; abstinence AM | Day 4; abstinence PM | Day 5; after scan, pre-smoking | Day 5; after smoking | |
| Progesterone 200 mg Capsules | 34.60 | 28.63 | 24.88 | 27.72 | 27.94 | 25.57 | 28.22 | 28.63 |
| Progesterone 200 mg Look-alike Capsules | 40.23 | 22.20 | 33.40 | 31.95 | 34.64 | 29.27 | 35.22 | 32.61 |
Visual Analog Scale (VAS) question: Irritable. Scale ranges from 0 to 100 with higher levels indicating greater intensity of symptom/feeling. (NCT01954966)
Timeframe: Day 2 (pre and post scan), day 3 (AM and PM), day 4 (AM and PM), day 5 (pre and post smoking session)
| Intervention | score on a scale (Mean) | |||||||
|---|---|---|---|---|---|---|---|---|
| Day 2; pre-1st scan | Day 2; post-2nd scan | Day 3; abstinence AM | Day 3; abstinence PM | Day 4; abstinence AM | Day 4; abstinence PM | Day 5; after scan, pre-smoking | Day 5; after smoking | |
| Progesterone 200 mg Capsules | 7.50 | 13.20 | 24.80 | 23.97 | 30.79 | 26.50 | 23.23 | 13.45 |
| Progesterone 200 mg Look-alike Capsules | 5.71 | 13.01 | 24.56 | 25.49 | 29.58 | 30.11 | 22.96 | 15.52 |
Visual Analog Scale (VAS) question: Nauseous. Scale ranges from 0 to 100 with higher levels indicating greater intensity of symptom/feeling. (NCT01954966)
Timeframe: Day 2 (pre and post scan), day 3 (AM and PM), day 4 (AM and PM), day 5 (pre and post smoking session)
| Intervention | score on a scale (Mean) | |||||||
|---|---|---|---|---|---|---|---|---|
| Day 2; pre-1st scan | Day 2; post-2nd scan | Day 3; abstinence AM | Day 3; abstinence PM | Day 4; abstinence AM | Day 4; abstinence PM | Day 5; after scan, pre-smoking | Day 5; after smoking | |
| Progesterone 200 mg Capsules | 5.52 | 6.31 | 6.01 | 8.07 | 6.07 | 6.60 | 6.51 | 8.00 |
| Progesterone 200 mg Look-alike Capsules | 4.92 | 5.43 | 10.44 | 9.85 | 8.22 | 10.29 | 10.34 | 11.41 |
Visual Analog Scale (VAS) question: Nervous. Scale ranges from 0 to 100 with higher levels indicating greater intensity of symptom/feeling. (NCT01954966)
Timeframe: Day 2 (pre and post scan), day 3 (AM and PM), day 4 (AM and PM), day 5 (pre and post smoking session)
| Intervention | score on a scale (Mean) | |||||||
|---|---|---|---|---|---|---|---|---|
| Day 2; pre-1st scan | Day 2; post-2nd scan | Day 3; abstinence AM | Day 3; abstinence PM | Day 4; abstinence AM | Day 4; abstinence PM | Day 5; after scan, pre-smoking | Day 5; after smoking | |
| Progesterone 200 mg Capsules | 13.24 | 10.91 | 7.19 | 9.56 | 9.36 | 10.83 | 10.79 | 7.64 |
| Progesterone 200 mg Look-alike Capsules | 10.26 | 8.46 | 8.22 | 9.24 | 11.37 | 10.66 | 12.15 | 11.94 |
Visual Analog Scale (VAS) question: Relaxed. Scale ranges from 0 to 100 with higher levels indicating greater intensity of symptom/feeling. (NCT01954966)
Timeframe: Day 2 (pre and post scan), day 3 (AM and PM), day 4 (AM and PM), day 5 (pre and post smoking session)
| Intervention | score on a scale (Mean) | |||||||
|---|---|---|---|---|---|---|---|---|
| Day 2; pre-1st scan | Day 2; post-2nd scan | Day 3; abstinence AM | Day 3; abstinence PM | Day 4; abstinence AM | Day 4; abstinence PM | Day 5; after scan, pre-smoking | Day 5; after smoking | |
| Progesterone 200 mg Capsules | 72.66 | 67.77 | 63.87 | 57.69 | 57.83 | 63.46 | 62.45 | 67.99 |
| Progesterone 200 mg Look-alike Capsules | 73.87 | 63.65 | 55.85 | 54.08 | 55.37 | 63.45 | 67.65 | 67.55 |
Visual Analog Scale (VAS) question: Sad. Scale ranges from 0 to 100 with higher levels indicating greater intensity of symptom/feeling. (NCT01954966)
Timeframe: Day 2 (pre and post scan), day 3 (AM and PM), day 4 (AM and PM), day 5 (pre and post smoking session)
| Intervention | score on a scale (Mean) | |||||||
|---|---|---|---|---|---|---|---|---|
| Day 2; pre-1st scan | Day 2; post-2nd scan | Day 3; abstinence AM | Day 3; abstinence PM | Day 4; abstinence AM | Day 4; abstinence PM | Day 5; after scan, pre-smoking | Day 5; after smoking | |
| Progesterone 200 mg Capsules | 3.95 | 6.77 | 5.67 | 4.36 | 8.54 | 7.32 | 3.87 | 2.95 |
| Progesterone 200 mg Look-alike Capsules | 2.09 | 4.48 | 10.51 | 9.07 | 8.47 | 8.65 | 12.47 | 5.92 |
Visual Analog Scale (VAS) question: Headache. Scale ranges from 0 to 100 with higher levels indicating greater intensity of symptom/feeling. (NCT01954966)
Timeframe: Day 2 (pre and post scan), day 3 (AM and PM), day 4 (AM and PM), day 5 (pre and post smoking session)
| Intervention | score on a scale (Mean) | |||||||
|---|---|---|---|---|---|---|---|---|
| Day 2; pre-1st scan | Day 2; post-2nd scan | Day 3; abstinence AM | Day 3; abstinence PM | Day 4; abstinence AM | Day 4; abstinence PM | Day 5; after scan, pre-smoking | Day 5; after smoking | |
| Progesterone 200 mg Capsules | 54.17 | 50.61 | 51.43 | 48.14 | 49.67 | 50.48 | 52.74 | 54.26 |
| Progesterone 200 mg Look-alike Capsules | 57.46 | 51.46 | 50.34 | 47.04 | 50.71 | 49.27 | 56.19 | 53.12 |
Visual Analog Scale (VAS) question: Tired. Scale ranges from 0 to 100 with higher levels indicating greater intensity of symptom/feeling. (NCT01954966)
Timeframe: Day 2 (pre and post scan), day 3 (AM and PM), day 4 (AM and PM), day 5 (pre and post smoking session)
| Intervention | score on a scale (Mean) | |||||||
|---|---|---|---|---|---|---|---|---|
| Day 2; pre-1st scan | Day 2; post-2nd scan | Day 3; abstinence AM | Day 3; abstinence PM | Day 4; abstinence AM | Day 4; abstinence PM | Day 5; after scan, pre-smoking | Day 5; after smoking | |
| Progesterone 200 mg Capsules | 24.15 | 29.67 | 21.64 | 30.82 | 31.73 | 30.69 | 33.94 | 31.22 |
| Progesterone 200 mg Look-alike Capsules | 18.62 | 40.92 | 27.24 | 35.53 | 27.99 | 28.51 | 32.06 | 34.79 |
4 reviews available for aspartic acid and Alcoholism
| Article | Year |
|---|---|
Brain metabolite alterations related to alcohol use: a meta-analysis of proton magnetic resonance spectroscopy studies.
Topics: Alcoholism; Aspartic Acid; Brain; Choline; Glutamic Acid; Humans; Proton Magnetic Resonance Spectros | 2022 |
Neurochemistry of drug action: insights from proton magnetic resonance spectroscopic imaging and their relevance to addiction.
Topics: Alcoholism; Animals; Appetite Stimulants; Aspartic Acid; Brain; Choline; Cocaine; Creatine; Glutamic | 2010 |
Association of an Asn40Asp (A118G) polymorphism in the mu-opioid receptor gene with substance dependence: a meta-analysis.
Topics: Alcoholism; Asparagine; Aspartic Acid; Gene Frequency; Genetic Predisposition to Disease; Humans; Po | 2006 |
N-acetylaspartate as a marker of neuronal injury in neurodegenerative disease.
Topics: Aging; Alcoholism; Amyotrophic Lateral Sclerosis; Aspartic Acid; Biomarkers; Brain; Brain Injuries; | 2006 |
8 trials available for aspartic acid and Alcoholism
| Article | Year |
|---|---|
Effects of ibudilast on central and peripheral markers of inflammation in alcohol use disorder: A randomized clinical trial.
Topics: Alcohol Drinking; Alcoholism; Animals; Aspartic Acid; C-Reactive Protein; Choline; Creatine; Humans; | 2022 |
Naltrexone vs Placebo for the Treatment of Alcohol Dependence: A Randomized Clinical Trial.
Topics: Adult; Alcohol Drinking; Alcoholism; Alleles; Asparagine; Aspartic Acid; Double-Blind Method; Drug A | 2015 |
Naltrexone selectively elevates GABAergic neuroactive steroid levels in heavy drinkers with the Asp40 allele of the OPRM1 gene: a pilot investigation.
Topics: Adult; Alcohol Drinking; Alcoholism; Alleles; Amino Acid Substitution; Aspartic Acid; Double-Blind M | 2010 |
Cortical gamma-aminobutyric acid levels and the recovery from ethanol dependence: preliminary evidence of modification by cigarette smoking.
Topics: Adult; Alcoholism; Aspartic Acid; Choline; Creatine; gamma-Aminobutyric Acid; Humans; Magnetic Reson | 2006 |
Cortical gamma-aminobutyric acid levels and the recovery from ethanol dependence: preliminary evidence of modification by cigarette smoking.
Topics: Adult; Alcoholism; Aspartic Acid; Choline; Creatine; gamma-Aminobutyric Acid; Humans; Magnetic Reson | 2006 |
Cortical gamma-aminobutyric acid levels and the recovery from ethanol dependence: preliminary evidence of modification by cigarette smoking.
Topics: Adult; Alcoholism; Aspartic Acid; Choline; Creatine; gamma-Aminobutyric Acid; Humans; Magnetic Reson | 2006 |
Cortical gamma-aminobutyric acid levels and the recovery from ethanol dependence: preliminary evidence of modification by cigarette smoking.
Topics: Adult; Alcoholism; Aspartic Acid; Choline; Creatine; gamma-Aminobutyric Acid; Humans; Magnetic Reson | 2006 |
An evaluation of mu-opioid receptor (OPRM1) as a predictor of naltrexone response in the treatment of alcohol dependence: results from the Combined Pharmacotherapies and Behavioral Interventions for Alcohol Dependence (COMBINE) study.
Topics: Acamprosate; Adult; Alcoholism; Alleles; Amino Acid Substitution; Asparagine; Aspartic Acid; Cogniti | 2008 |
[Lithium in the treatment of chronic alcoholic patients with brain damage--a controlled study].
Topics: Adult; Alcohol Drinking; Alcoholism; Aspartic Acid; Brain Damage, Chronic; Double-Blind Method; Huma | 1991 |
[Controlled clinical trial of a new substance with hepatotropic activity, carried out with an experimental cross-over plan in double-blind conditions].
Topics: Adult; Aged; Alcoholism; Amino Acids; Aspartic Acid; Chemical and Drug Induced Liver Injury; Chronic | 1972 |
[Clinical experiences in liver diseases (specially in patients with fatty liver due to alcoholism and food poisoning) under monotherapy with ornithine aspartate].
Topics: Adolescent; Adult; Alcoholism; Aspartic Acid; Clinical Trials as Topic; Dipeptides; Drug Tolerance; | 1973 |
47 other studies available for aspartic acid and Alcoholism
| Article | Year |
|---|---|
Brain N-Acetyl Aspartate and associations with cognitive impairment in alcohol dependent patients.
Topics: Adult; Aged; Alcoholism; Aspartic Acid; Brain Chemistry; Cognitive Dysfunction; Female; Humans; Magn | 2020 |
Brain Glutamate, GABA, and Glutamine Levels and Associations with Recent Drinking in Treatment-Naïve Individuals with Alcohol Use Disorder Versus Light Drinkers.
Topics: Adult; Alcohol Drinking; Alcoholism; Aspartic Acid; Case-Control Studies; Female; gamma-Aminobutyric | 2019 |
Increased extracellular glutamate in the nucleus accumbens promotes excessive ethanol drinking in ethanol dependent mice.
Topics: Alcohol Drinking; Alcoholism; Amino Acids; Analysis of Variance; Animals; Aspartic Acid; Bridged Bic | 2014 |
A preliminary examination of cortical neurotransmitter levels associated with heavy drinking in posttraumatic stress disorder.
Topics: Adult; Aged; Alcoholism; Aspartic Acid; Cerebral Cortex; Choline; Comorbidity; Creatine; gamma-Amino | 2014 |
Associations Between Recent Heavy Drinking and Dorsal Anterior Cingulate N-Acetylaspartate and Glutamate Concentrations in Non-Treatment-Seeking Individuals with Alcohol Dependence.
Topics: Adult; Alcohol Drinking; Alcoholism; Aspartic Acid; Biomarkers; Female; Glutamic Acid; Gyrus Cinguli | 2016 |
Brain metabolite levels in recently sober individuals with alcohol use disorder: Relation to drinking variables and relapse.
Topics: Adult; Alcohol Abstinence; Alcohol Drinking; Alcoholism; Aspartic Acid; Brain; Choline; Chronic Dise | 2016 |
Negative Association Between MR-Spectroscopic Glutamate Markers and Gray Matter Volume After Alcohol Withdrawal in the Hippocampus: A Translational Study in Humans and Rats.
Topics: Adult; Alcohol Abstinence; Alcoholism; Animals; Aspartic Acid; Biomarkers; Female; Glutamic Acid; Gr | 2017 |
MRSI and DTI: a multimodal approach for improved detection of white matter abnormalities in alcohol and nicotine dependence.
Topics: Alcoholism; Anisotropy; Aspartic Acid; Basal Ganglia; Brain; Diffusion Magnetic Resonance Imaging; F | 2009 |
Alcohol abuse and acute behavioural disturbances in a 24-year-old patient. Diagnosis: Marchiafava-Bignami disease (MBD).
Topics: Alcohol-Induced Disorders, Nervous System; Alcoholism; Aspartic Acid; Choline; Corpus Callosum; Crea | 2009 |
Bipolar disorder comorbid with alcoholism: a 1H magnetic resonance spectroscopy study.
Topics: Adult; Age Factors; Alcoholism; Analysis of Variance; Aspartic Acid; Bipolar Disorder; Brain; Comorb | 2010 |
Brain metabolite changes in alcoholism: localized proton magnetic resonance spectroscopy study of the occipital lobe.
Topics: Adult; Alcoholism; Aspartic Acid; Case-Control Studies; Choline; Creatine; Humans; Image Interpretat | 2011 |
Brain injury and recovery following binge ethanol: evidence from in vivo magnetic resonance spectroscopy.
Topics: Alcoholism; Analysis of Variance; Animals; Aspartic Acid; Body Weight; Brain Injuries; Brain Mapping | 2010 |
Metabolite levels in the brain reward pathway discriminate those who remain abstinent from those who resume hazardous alcohol consumption after treatment for alcohol dependence.
Topics: Adult; Alcohol Drinking; Alcoholism; Aspartic Acid; Brain; Creatine; Female; Follow-Up Studies; Huma | 2010 |
Body mass index is associated with brain metabolite levels in alcohol dependence--a multimodal magnetic resonance study.
Topics: Adult; Aged; Alcohol Drinking; Alcoholism; Aspartic Acid; Body Mass Index; Brain; Choline; Creatine; | 2010 |
Chronic cigarette smoking in alcohol dependence: associations with cortical thickness and N-acetylaspartate levels in the extended brain reward system.
Topics: Adult; Aged; Alcoholism; Aspartic Acid; Behavior, Addictive; Brain Mapping; Case-Control Studies; Ce | 2013 |
Influence of OPRM1 Asn40Asp variant (A118G) on [11C]carfentanil binding potential: preliminary findings in human subjects.
Topics: Adult; Alcoholism; Asparagine; Aspartic Acid; Carbon Radioisotopes; Female; Fentanyl; Genetic Variat | 2013 |
Effect of metabotropic glutamate receptor 3 genotype on N-acetylaspartate levels and neurocognition in non-smoking, active alcoholics.
Topics: Adult; Alcoholism; Aspartic Acid; Cognition; Executive Function; Genotype; Humans; Magnetic Resonanc | 2012 |
Effects of alcoholism and gender on brain metabolism.
Topics: Adult; Age Factors; Alcoholism; Aspartic Acid; Brain; Creatine; Female; Frontal Lobe; Humans; Inosit | 2003 |
Proton MR spectroscopic studies of chronic alcohol exposure on the rat brain.
Topics: Alcoholism; Animals; Aspartic Acid; Brain; Choline; Chronic Disease; Creatine; Magnetic Resonance Sp | 2003 |
[APROPOS OF THE CLINICAL INDICATIONS OF A NEW DRINKABLE ENRICHED LIVER EXTRACT OF THE ANTITOXIC FRACTION].
Topics: Alcoholic Intoxication; Alcoholism; Anemia; Aspartic Acid; Asthenia; Humans; Liver Cirrhosis; Liver | 1964 |
Attention, learning, and memory in posttraumatic stress disorder.
Topics: Alcoholism; Anthropometry; Aspartic Acid; Attention; Hippocampus; Humans; Learning; Male; Memory Dis | 2004 |
Cortical NAA deficits in HIV infection without dementia: influence of alcoholism comorbidity.
Topics: Adult; Alcoholism; Aspartic Acid; Brain Mapping; Case-Control Studies; Cerebral Cortex; Choline; Com | 2005 |
Monitoring the effects of chronic alcohol consumption and abstinence on brain metabolism: a longitudinal proton magnetic resonance spectroscopy study.
Topics: Adult; Aged; Alcoholism; Aspartic Acid; Brain Chemistry; Creatine; Female; Functional Laterality; Gl | 2005 |
Brain metabolite concentrations and neurocognition during short-term recovery from alcohol dependence: Preliminary evidence of the effects of concurrent chronic cigarette smoking.
Topics: Adult; Alcoholism; Aspartic Acid; Brain Chemistry; Cerebral Cortex; Choline; Cognition; Cross-Sectio | 2006 |
Get sober; stay sober.
Topics: Alcoholism; Aspartic Acid; Brain; Brain Diseases; Choline; Creatine; Humans; Magnetic Resonance Spec | 2007 |
Manifestations of early brain recovery associated with abstinence from alcoholism.
Topics: Adult; Alcoholism; Aspartic Acid; Atrophy; Attention; Brain; Brain Chemistry; Cerebellum; Choline; C | 2007 |
Chronic cigarette smoking modulates injury and short-term recovery of the medial temporal lobe in alcoholics.
Topics: Adult; Aged; Alcohol Amnestic Disorder; Alcoholism; Aspartic Acid; Atrophy; Choline; Cross-Sectional | 2008 |
Abnormal N-acetylaspartate in hippocampus and anterior cingulate in posttraumatic stress disorder.
Topics: Adult; Alcoholism; Algorithms; Aspartic Acid; Atrophy; Combat Disorders; Comorbidity; Conditioning, | 2008 |
Are treated alcoholics representative of the entire population with alcohol use disorders? A magnetic resonance study of brain injury.
Topics: Adult; Alcohol-Related Disorders; Alcoholism; Aspartic Acid; Brain; Choline; Female; Humans; Magneti | 2008 |
[Physostigmine as delirium-preventive agent in ambulatory alcohol withdrawal].
Topics: Alcohol Withdrawal Delirium; Alcoholism; Ambulatory Care; Aspartic Acid; Humans; Lithium; Physostigm | 1983 |
[Lithium aspartate in drug dependence].
Topics: Adult; Alcoholism; Aspartic Acid; Bipolar Disorder; Female; Humans; Lithium; Male; Middle Aged; Subs | 1982 |
Brain proton magnetic resonance spectroscopy studies in recently abstinent alcoholics.
Topics: Adult; Aged; Alcoholism; Aspartic Acid; Atrophy; Brain; Cerebellum; Choline; Female; Humans; Magneti | 1995 |
Amino acid neurotransmitters in alcohol withdrawal.
Topics: Adult; Alcohol Withdrawal Delirium; Alcoholism; Amino Acids; Aspartic Acid; gamma-Aminobutyric Acid; | 1994 |
Increased glutamatergic neurotransmission and oxidative stress after alcohol withdrawal.
Topics: Adult; Alcoholism; Aspartic Acid; Dipeptides; Ethanol; Excitatory Amino Acids; Female; gamma-Aminobu | 1998 |
Central effects of acamprosate: part 1. Acamprosate blocks the glutamate increase in the nucleus accumbens microdialysate in ethanol withdrawn rats.
Topics: Acamprosate; Alanine; Alcohol Deterrents; Alcoholism; Animals; Arginine; Aspartic Acid; Chromatograp | 1998 |
Localized proton magnetic resonance spectroscopy of the cerebellum in detoxifying alcoholics.
Topics: Adult; Aged; Alcoholism; Aspartic Acid; Atrophy; Cerebellum; Choline; Female; Humans; Magnetic Reson | 1999 |
Elevated myo-inositol in gray matter of recently detoxified but not long-term abstinent alcoholics: a preliminary MR spectroscopy study.
Topics: Adult; Alcoholism; Analysis of Variance; Aspartic Acid; Brain; Choline; Humans; Inositol 1,4,5-Trisp | 2000 |
Metabolic changes in rat brain after prolonged ethanol consumption measured by 1H and 31P MRS experiments.
Topics: Adenosine Triphosphate; Alcohol Drinking; Alcoholism; Animals; Aspartic Acid; Astrocytes; Brain; Cho | 2000 |
Chemical pathology in brain white matter of recently detoxified alcoholics: a 1H magnetic resonance spectroscopy investigation of alcohol-associated frontal lobe injury.
Topics: Adult; Alcoholism; Aspartic Acid; Brain; Choline; Creatine; Female; Frontal Lobe; Humans; Inositol; | 2001 |
[Alcohol-induced morphologic and biochemical corneal changes].
Topics: Acetaldehyde; Alcoholism; Amino Acid Isomerases; Aspartic Acid; Cell Count; Cornea; Corneal Stroma; | 2002 |
Ischemia-induced glutamate release in rat frontoparietal cortex after chronic alcohol and withdrawal.
Topics: Alcoholism; Animals; Aspartic Acid; Central Nervous System Depressants; Dialysis Solutions; Ethanol; | 2002 |
Molecular injury to mitochondria produced by ethanol and acetaldehyde.
Topics: Acetaldehyde; Adenosine Triphosphatases; Alcohol Oxidoreductases; Alcoholism; Animals; Aspartic Acid | 1975 |
Ethanol oxidation by isolated hepatocytes from ethanol-treated and control rats; factors contributing to the metabolic adaptation after chronic ethanol consumption.
Topics: Alcoholism; Animals; Aspartic Acid; Ethanol; Humans; In Vitro Techniques; Liver; Malates; Male; Mito | 1978 |
[Arginine aspartate effects on rabbit acute and chronic alcoholization (author's transl)].
Topics: Alcoholic Intoxication; Alcoholism; Animals; Arginine; Aspartic Acid; Drug Interactions; Ethanol; Fe | 1978 |
Hypokalemic myopathy due to chronic alcoholism.
Topics: Adult; Alcoholism; Aspartic Acid; Creatine Kinase; Electromyography; Humans; Hypokalemia; Male; Midd | 1976 |
[Clinical trial of arginine aspartate in secondary sexual impotence].
Topics: Alcoholism; Arginine; Aspartic Acid; Disulfiram; Drug Tolerance; Erectile Dysfunction; Humans; Male; | 1972 |
[Treatment with association of aminoacids of dysmnesic disturbances in chronic alcoholics: some clinical and psychometric findings].
Topics: Adult; Alcohol Amnestic Disorder; Alcoholism; Aspartic Acid; Citrulline; Humans; Male; Middle Aged | 1965 |